MB710, an aminobenzothiazole derivative, stabilizes the oncogenic p53 mutation Y220C by binding tightly to the Y220C pocket, enhancing the stability of p53-Y220C with a dissociation constant (Kd) of 4.1 μM. This compound exhibits anticancer activity in cell lines harboring the p53-Y220C mutation [1].

MB710 (0-200 μM; 72 hours) shows relatively low toxicity against all tested cell lines at concentrations up to 60 μM, while showing initial selective viability reduction at higher concentrations [1]. MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC 50 s of 90, 120, >120, >120 μM, respectively [1]. MB710 (0-120 μM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C [1]. Cell Viability Assay [1] Cell Line: NUGC3 (mutant p53 Y220C), HUH-7 (mutant p53 Y220C), NUGC4 (p53 WT), HUH-6 cells (p53 WT) Concentration: 0-200 μM Incubation Time: 72 hours Result: Showed relatively low toxicity against all cell lines tested at concentrations up to 60 μM. NUGC3 was the most sensitive cell line.